Preliminary analysis of a phase 2b, randomized, active-control study of flonoltinib maleate (FM) vs. ruxolitinib in intermediate-2 or high-risk myelofibrosis patients
Year: 2025
Type: conference-abstract
Source: Blood
Institutions: Sichuan University, West China Hospital of Sichuan University, State Key Laboratory of Biotherapy, Binzhou Medical University, Sheng Jing Hospital, China Medical University, Gansu Provincial Hospital, Henan Cancer Hospital, Chengde Medical University, The Affiliated Yongchuan Hospital of Chongqing Medical University, Fujian Medical University, Union Hospital, Guangxi Medical University, First Affiliated Hospital of GuangXi Medical University, Tongji Hospital, Huazhong University of Science and Technology, Xian Central Hospital, University of Science and Technology of China, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417011693